Phase 4 N=20 Photodynamic Therapy (PDT) With Levulan and Blue Light for the Treatment of Actinic Cheilitis
Actinic Cheilitis
Primary: Number of Participants With a Change in Clearance From Baseline — 1; 1; 9; 4 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=9 Treatment of Oral Premalignant Lesions With 5-ALA PDT
Leukoplakia · Erythroplakia
Primary: Maximum Tolerated Dose — 8 J/cm2
Phase 4 N=30 Study of Daylight Photodynamic Therapy With Aminolevulinic Acid for Actinic Keratoses
Actinic Keratosis
Primary: Percent Change in the Number of Actinic Keratoses — -75 % change in number of actinic keratoses
Phase 4 N=551 Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis
Keratosis
Primary: Number of Participants Who Experienced an Adverse Event — 472 participants
Phase 3 N=490 Safety and Effectiveness Study of Imiquimod Creams for the Treatment of Actinic Keratoses (AKs)
Actinic Keratosis
Primary: Number of Participants With Complete Clearance of AK Lesions — 55; 41; 9 participants
Phase 3 N=26 Actinic Keratoses Treatment With Metvix® in Combination With Light
Actinic Keratoses
Primary: Mean Change From Baseline in Total Number of Treated Mild Lesions Per Side at Week 12 — 19.6; 20.0 number of lesions — p=0.8460
Phase 3 N=479 Safety and Effectiveness Study of Imiquimod Creams for Treatment of Actinic Keratoses (AKs)
Actinic Keratoses
Primary: Number of Participants With Complete Clearance of AK Lesions — 57; 49; 10 participants
Phase 2 N=83 Topical Perillyl Alcohol in Treating Patients With Sun Damaged Skin and Actinic Keratoses
Precancerous Condition
Primary: Change in Histopathology Score of Sun Damaged Skin by Treatment Group — 0.4; -0.1; 0.1 units on a scale — p=0.10
N/A N=10 Photodynamic Therapy With Levulan® +/- Topical Retinoid Pre-Treatment In The Treatment Of Actinic Keratoses
ACTINIC KERATOSES
Primary: Change in Lesion Counts in 25 cm2 Target Area Relative to Baseline. — -72; -37.5 lesions
Phase 3 N=20 Short Incubation Methylaminolevulinate Photodynamic Therapy Without Occlusion
Actinic Keratosis
Primary: Mean Number of Facial Actinic Keratoses at Week 12 — 2.70 Lesions
Phase 2 N=168 Activity & Safety Study of KX2-391 Ointment in Participants With Actinic Keratosis on the Face or Scalp
Actinic Keratosis
Primary: Percentage of Participants With Complete Response of Actinic Keratosis — 43; 32 percentage of participants
Phase 2 N=166 Controlled Study of the Occurrence of Actinic Keratosis on the Face After Cryotherapy + Aminolevulinic Acid (ALA) Photodynamic Therapy
Actinic Keratosis
Primary: Total Number of AKs in Treatment Area — 3.0; 2.1; 4.7 lesions — p=0.0166
Phase 3 N=329 A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp
Actinic Keratosis
Primary: Complete Clearance of AKs at Week 11 — 101; 80 participants
Phase 2 N=14 Daylight-mediated Photodynamic Therapy of Actinic Keratoses:Comparing 0.2%HAL With 16%MAL
Actinic Keratoses
Primary: Histological Lesion Clearance — 38.5; 69.2 percentage of complete histological clea
Phase 2 N=21 Genomic Markers Before and After Treatment of Actinic Keratosis With Imiquimod 3.75% Cream
Actinic Keratosis
Primary: Number of Responders — 19 Participants
Phase 3 N=557 Multicenter Study to Assess the Efficacy and Safety of Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) Versus Vehicle Cream for Actinic Keratosis of the Face
Actinic Keratoses
Primary: Percentage of Participants With Complete Response at Week 12 — 25.3; 23.0 percentage of participants
Phase 2 N=75 Vitamin D Supplementation as a Neoadjuvant for Photodynamic Therapy of Actinic Keratoses
Actinic Keratosis
Primary: Clinical PDT Response as Measured by Percent Change in AK Lesions From Baseline to 3 Months — 59.1; 72.5 Percent change of AK lesions
Phase 2 N=235 Short-incubation Levulan Photodynamic Therapy Versus Vehicle for Face/Scalp Actinic Keratosis (AK)
Actinic Keratosis
Primary: Complete Clearance Rate — 14; 7; 13; 8 participants — p=0.0041
Phase 2 N=83 Study to Evaluate the Efficacy, Safety, and Tolerability of Topical VDA-1102 Ointment in Subjects With Actinic Keratosis
Actinic Keratosis
Primary: Complete Clearance Rate — 7; 9 Participants
Phase 2 N=165 The Efficacy and Tolerability of Oleogel-S-10 in Patients With Actinic Keratoses
Actinic Keratoses
Primary: Objective Response of the Marker Actinic Keratosis, Defined as Histologically Complete or Partial Clearance. — 22; 17; 19; 25 participants — p=0.60
Phase 3 N=131 Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp
Actinic Keratosis
Primary: Participant Complete Response Rate (CRR) — 68.4; 6.9 Percentage of participants
Phase 2 N=70 Levulan PDT Versus Vehicle for Extremity Actinic Keratoses (AK)
Keratosis, Actinic
Primary: Lesion Clearance Rate — 88.7; 70.0; 16.7; 5.6 percentage of lesions cleared
Phase 3 N=269 Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities
Actinic Keratosis
Primary: Complete Clearance Rate — 42; 17 participants — p=0.0001
Phase 3 N=307 Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up
Actinic Keratosis
Primary: Percentage of Participants With Complete Clearance of Actinic Keratosis (AK) — 31.3; 1.0 percentage of participants — p=<0.001
Phase 3 N=60 Cryosurgery and Cream Combination for Actinic Keratosis
Actinic Keratosis
Primary: Number Participants With 100% Clearance — 12; 13 Participants
Phase 4 N=27 Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses
Actinic Keratoses
Primary: Change From Baseline in Actinic Keratoses Count at 4-8 Weeks Post-treatment — -73.2; -62.0 Percent change
Phase 2 N=93 Efficacy and Safety of VDA-1102 Ointment in the Treatment of Actinic Keratosis
Actinic Keratosis
Primary: Change From Baseline in the Number of Actinic Keratosis Lesions in the Treatment Field on Day 56 — -1.54; -1.34; -1.94 lesions — p=0.9518
Phase 1 N=24 PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal Microscopy
Actinic Keratosis
Primary: Change in Degree of Infiltration — 1.42 percentage change
Phase 2 N=189 Safety of LEO 43204 for Actinic Keratosis Applied on Face/Chest, Scalp and Trunk/Extremities, Respectively
Actinic Keratosis
Primary: Number of Participants Experiencing DLTs (Dose Limiting Toxicities) Based on LSRs (Local Skin Reactions) — 9; 0; 11 Participants
Phase 3 N=255 A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations
Actinic Keratoses
Primary: Patients With Complete Clearance of Actinic Keratosis (AKs) — 35; 6 Participants — p=<0.0001